Ultragenyx Pharmaceutical (RARE) Garnering Bullish Sentiment With Forthcoming GTX-102 Phase 3 Angelman Trial
Summary
On April 16, Morgan Stanley increased the price target for Ultragenyx Pharmaceutical Inc.
Description
On April 16, Morgan Stanley increased the price target for Ultragenyx Pharmaceutical Inc.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source